Kai Health Care Co., Ltd. announced that it expects to receive KRW 5 billion in funding from FutureChem Co.,Ltd
September 06, 2017
Share
Kai Health Care Co., Ltd. announced a private placement of 90,976 shares at a price of KRW 54,960 per share for gross proceeds of KRW 5,000,040,960 on September 7, 2017. The transaction will include participation from returning investor, FutureChem Co.,Ltd (KOSDAQ:A220100). Post the closing of the transaction, the number of shares will increase from 90,964 to 181,940 and the investor will hold 100% stake in the company. The shares will be issued through third party capital increase method. The payment date is September 13, 2017. The transaction has been approved by the board of directors of the investor. The company reported total assets of KRW 2,514,000,000, total liabilities of KRW 2,127,000,000, shareholders equity of KRW 387,000,000, revenue of KRW 2,333,000,000, and net loss of KRW -942,000,000 for the year ended December 31, 2016.
FutureChem. Co.,Ltd is a Korea-based company principally engaged in the manufacture and distribution of radiopharmaceuticals. The Company manufactures radiopharmaceuticals including radiopharmaceuticals for diagnosis of various cancers such as lung cancer and for the early diagnosis of Parkinson's disease and Alzheimer's disease. The Company also produces medical automation modules such as cubes and disposable goods including disposable cassettes, reagent kits, radio-caps and kryptofix kits; productions of photon emission tomography (PET) and single photon emission computed tomography (SPECT) precursors for radiopharmaceuticals and other chemicals such as metal chelating agents, fluorescence probes, peptides.